23
23J.F Promis Neurosciences Inc
- Market cap
- EUR 26.9M
- P/E
- -
- P/B
- 0.64x
- ROE
- -80.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 23J.F undervalued?
Graham numberThe Graham number of Promis Neurosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Promis Neurosciences Inc fundamental analysis
No fundamental analysis for Promis Neurosciences Inc yet.
Promis Neurosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Promis Neurosciences Inc
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the tr…
Full company profilePromis Neurosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Promis Neurosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.69K | 9.90K | 475.00 | 1.20K | 1.79K | 16.4K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.44M | -6.01M | -10.2M | -7.40M | -5.66M | -10.5M | -23.4M | -14.3M | -16.8M | -40.2M | -41.8M |
| EBITDA | - | -6.01M | -10.2M | -7.39M | -5.65M | -11.2M | -17.8M | -13.0M | 2.86M | -39.7M | -41.8M |
| Net Income | -3.45M | -6.02M | -10.2M | -7.40M | -5.66M | -11.8M | -18.1M | -13.2M | 2.78M | -39.7M | -39.9M |
| EPS | - | -0.03 | -0.04 | -0.03 | -0.02 | -0.03 | -53 | -17 | 2.13 | -18 | -4.45 |
| Balance Sheet | |||||||||||
| Total Assets | 968K | 2.17M | 2.97M | 2.07M | 1.38M | 22.5M | 6.92M | 13.6M | 18.9M | 9.18M | 56.7M |
| Total Liabilities | 898K | 637K | 1.81M | 1.68M | 2.40M | 15.0M | 8.27M | 9.87M | 2.42M | 10.4M | 7.29M |
| Shareholders' Equity | 69.4K | 1.53M | 1.16M | 398K | -1.02M | 7.48M | -1.35M | 3.75M | 16.5M | -1.26M | 49.4M |
| Cash & Short-term Investments | 712K | 1.69M | 2.39M | 1.66M | 1.03M | 21.4M | 5.88M | 12.6M | 13.3M | 6.12M | 53.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.54M | -5.70M | -8.64M | -6.09M | -4.35M | -11.8M | -17.0M | -10.8M | -27.2M | -28.1M | -45.5M |
| Capital Expenditure | 0.00 | 109K | 109K | 109K | 109K | 7.68K | 1.98K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -5.70M | -8.64M | -6.09M | -4.46M | -11.8M | -17.0M | -10.8M | -27.2M | -28.1M | -45.5M |
| Ratios | |||||||||||
| ROE | -4,976.0% | -392.6% | -879.3% | -1,857.8% | - | -157.6% | - | -352.0% | 16.9% | - | -80.9% |
| ROA | -357.0% | -277.3% | -342.8% | -356.7% | -408.9% | -52.5% | -260.8% | -97.0% | 14.7% | -432.6% | -70.5% |
| Net Profit Margin | -128,390.0% | -60,838.5% | -2,140,431.6% | -615,329.4% | -316,865.8% | -71,812.4% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Promis Neurosciences Inc dividends
Promis Neurosciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Nov 28, 2025.
Who owns Promis Neurosciences Inc
- Insiders 12.29%
- Institutions 77.07%
- Public & others 10.64%
- Shares outstanding 8.97M
- Free float 4.35M
Promis Neurosciences Inc company profile
- Company name
- Promis Neurosciences Inc
- Ticker
- 23J.F
- ISIN
- CA74346M5054
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- 1920 Yonge Street, Toronto, ON, Canada, M4S 3E2
- Phone
- 416 847 6898
- Website
- promisneurosciences.com
About Promis Neurosciences Inc
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Promis Neurosciences Inc management
9- Mr. Eugene W. WilliamsCo-Founder & Chairman · born 1959
- Mr. Neil K. Warma M.B.A.CEO, President, Compliance Officer & Director · born 1963
- Dr. Neil R. Cashman M.D.Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director · born 1952
- Dr. Johanne Kaplan Ph.D.Chief Development Officer · born 1960
- Dr. Larry Douglas Altstiel M.D., Ph.D.Chief Medical Officer · born 1950
- Mr. Daniel E. Geffken M.B.A.Chief Financial Officer · born 1957
- Dr. David Wishart Ph.D.Chief Physics Officer
- Mr. Dennis Chen Ph.D.Head of Manufacturing & Senior Consultant
- Dr. Ivana Rubino Ph.D.Chief Commercial Officer